<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930315</url>
  </required_header>
  <id_info>
    <org_study_id>CISLD-11</org_study_id>
    <nct_id>NCT04930315</nct_id>
  </id_info>
  <brief_title>SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma</brief_title>
  <official_title>SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib&#xD;
      mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab&#xD;
      adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to compare the efficacy and safety of camrelizumab + apatinib&#xD;
      mesylate neoadjuvant therapy combined with camrelizumab adjuvant therapy and camrelizumab&#xD;
      adjuvant therapy alone in patients with technically resectable hepatocellular carcinoma.&#xD;
      There are two groups:&#xD;
&#xD;
        1. Neoadjuvant and adjuvant group: (1) Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4&#xD;
           cycles；apatinib：250mg, po, qd, q2w, 3 cycles; (2) Operation; (3) Postoperation 4-8&#xD;
           weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles.&#xD;
&#xD;
        2. Adjuvant group: (1) Operation; (2) Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1,&#xD;
           q2w, Up to 12 cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year tumor recurrence-free rate</measure>
    <time_frame>Up to one years</time_frame>
    <description>The proportion of patients who had tumor recurrence (local, regional or distant) or death within 1 year after surgery, whichever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Overall survival (OS) refers to the time from enrollment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival (RFS)</measure>
    <time_frame>Up to 1 years</time_frame>
    <description>From radical resection to the date of the first documented tumor into recurrence or death from any cause, whichever occurred first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>Up to 1 years</time_frame>
    <description>The proportion of patients without death within 1 year after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>The proportion of patients with negative resection margin among patients undergoing surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathological response (MPR)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Number of participants experiencing the percentage of the non-viable cancer cells (necrotized or fibrotized) out of the surface expression of the total tumor area is &lt;10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>After neoadjuvant therapy, no evidence of malignant histology was found in the pathological examination of primary tumor or only carcinoma in situ was found</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical resection rate</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>the proportion of patients who can accept surgical resection after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Safety evaluation was done continuously during treatment by using CTCAE 5.0</time_frame>
    <description>Time Frame: 48 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>neoadjuvant and adjuvant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative：Camrelizumab ：200mg, iv, d1, q2w, 4 cycles；apatinib：250mg, po, qd, q2w, 3 cycles Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 8 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operation Postoperation 4-8 weeks，Camrelizumab ：200mg, iv, d1, q2w, Up to 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery</description>
    <arm_group_label>neoadjuvant and adjuvant group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>200mg, iv, d1, q2w, both in two groups</description>
    <arm_group_label>adjuvant group</arm_group_label>
    <arm_group_label>neoadjuvant and adjuvant group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1)Aged 18-70 years old, both genders.&#xD;
&#xD;
          -  2)Histologically confirmed diagnosis of HCC or strictly consistent with the clinical&#xD;
             diagnostic criteria for HCC according to AASLD guideline&#xD;
&#xD;
          -  3)BCLC stage was B / C, or CNLC stage was IIa-IIIb, but technically resectable (the&#xD;
             number of tumors was less than 7, accompanied by ipsilateral portal vein or hepatic&#xD;
             vein tumor thrombus formation, but no main portal vein, contralateral portal vein,&#xD;
             contralateral hepatic vein or inferior vena cava tumor thrombus, no extrahepatic&#xD;
             metastasis, estimated residual liver volume &gt; 30% [if patients with liver fibrosis,&#xD;
             residual liver volume &gt; 40%])&#xD;
&#xD;
          -  4)At least one measurable lesion that meet the mRECIST standard, and the lesion has&#xD;
             not received radiotherapy, or local treatments&#xD;
&#xD;
          -  5)Child-Pugh score: A grade&#xD;
&#xD;
          -  6)ECOG PS 0-1 points.&#xD;
&#xD;
          -  7)The function of vital organs meets the following requirements (excluding the use of&#xD;
             any blood component and cell growth factor within 14 days) :&#xD;
&#xD;
               1. Neutrophils ≥1.5×109/L&#xD;
&#xD;
               2. Platelet count ≥100×109/L&#xD;
&#xD;
               3. Hemoglobin ≥90g/L&#xD;
&#xD;
               4. Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal value (ULN)&#xD;
&#xD;
               5. AST or ALT levels ≤ 1.5 times the upper limit of normal value (ULN);&#xD;
&#xD;
               6. Serum albumin ≥ 30 g / L&#xD;
&#xD;
               7. Thyroid stimulating hormone (TSH) ≤ ULN&#xD;
&#xD;
               8. Subjects who did not receive anticoagulant therapy: International standardized&#xD;
                  ratio INR or Partial thromboplastin time APTT≤1.5×ULN; subjects received&#xD;
                  prophylactic anticoagulant therapy, INR≤1.5×ULN and APTT ≤ ULN within 14 days&#xD;
                  before the start of study treatment;&#xD;
&#xD;
               9. Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN) and&#xD;
                  creatinine clearance ≥60 ml/min (Cockcroft-Gault formula)&#xD;
&#xD;
          -  8)If HBsAg (+) and / or anti HCV (+), according to the results of HBV DNA or HCV RNA&#xD;
             detection, antiviral therapy should be carried out according to the standard&#xD;
&#xD;
          -  9)Women of childbearing age should with negative serum or urine pregnancy tests within&#xD;
             14 days prior to study inclusion and who must be non-lactating, and patient should&#xD;
             agree to use contraceptives (such as intrauterine devices, contraceptives or condoms)&#xD;
             during and within 60 days of the end of medication&#xD;
&#xD;
          -  10)Males with partner of childbearing age should agree to use contraceptives during&#xD;
             the study period and for 120 days after the end of the study period;&#xD;
&#xD;
          -  11)Subjects have good compliance and cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)Known hepatobiliary cell carcinoma, mixed cell carcinoma and fibre-lamellar cell&#xD;
             carcinoma;&#xD;
&#xD;
          -  2)Co-infection with hepatitis B and C, or co-infection with hepatitis B and D&#xD;
&#xD;
          -  3)Active malignancies other than HCC within 5 years or concurrently, except for cured&#xD;
             basal cell carcinoma of the skin and carcinoma in situ of the cervix and papillary&#xD;
             thyroid cancer&#xD;
&#xD;
          -  4)Subjects has received radical hepatectomy, systemic anticancer therapy for HCC&#xD;
             (mainly including systemic chemotherapy, molecular targeted therapy and CTLA-4, PD-1 /&#xD;
             PD-L1 monoclonal antibody immunotherapy) and local treatment for liver, including&#xD;
             TACE, TAE, tare or local ablation, radiotherapy, etc&#xD;
&#xD;
          -  5)Presence of the following within 3 months prior to study entry: myocardial&#xD;
             infarction, severe unstable angina, NYHA class 2 or higher cardiac insufficiency,&#xD;
             poorly controlled arrhythmias, symptomatic congestive heart failure, cerebrovascular&#xD;
             accident.&#xD;
&#xD;
          -  6)Having hypertension that cannot be well controlled by antihypertensive drug therapy&#xD;
             (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);Previous&#xD;
             history of hypertension crisis or hypertensive encephalopathy;&#xD;
&#xD;
          -  7)Active pulmonary tuberculosis or pulmonary tuberculosis history&#xD;
&#xD;
          -  8)Subject has any active autoimmune disease or history of autoimmune disease (such as,&#xD;
             but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism; Subjects with vitiligo or childhood asthma have been completely&#xD;
             relieved and may be included as adults without any intervention;Asthma requiring&#xD;
             medical intervention with bronchodilators will not be included);&#xD;
&#xD;
          -  9)Interstitial lung disease history or non-infectious pneumonia requiring oral or&#xD;
             intravenous steroid therapy&#xD;
&#xD;
          -  10)Subjects are receiving immunosuppressive, or systemic, or absorbable local hormone&#xD;
             therapy for immunosuppression purposes (&gt;10mg/ day prednisone or other therapeutic&#xD;
             hormones) and continue to receive such therapy within 2 weeks prior to enrollment;&#xD;
&#xD;
          -  11)Abnormal coagulation (INR &gt; 1.5 or APTT &gt; 1.5 x ULN) with bleeding tendency or on&#xD;
             thrombolytic or anticoagulant therapy&#xD;
&#xD;
          -  12)The presence of clinically significant bleeding symptoms or a definite bleeding&#xD;
             tendency within 3 months prior to study entry, such as gastrointestinal bleeding,&#xD;
             hemorrhagic gastric ulcer, fecal occult blood +++ or more at baseline, or vasculitis.&#xD;
             Gastroscopy was performed if fecal occult blood was positive at baseline, or if it was&#xD;
             an observable bloody stool. If gastroscopy indicated severe esophageal varices, it&#xD;
             could not be included&#xD;
&#xD;
          -  13)Known hypersensitivity to apatinib, camrelizumab or drug excipients; or severe&#xD;
             allergic reactions to other monoclonal antibodies&#xD;
&#xD;
          -  14)Subject has active infection or unexplained fever of &gt;38.5 degrees during screening&#xD;
             and before first administration (subject's fever due to tumor can be enrolled&#xD;
             according to the investigator's judgment);&#xD;
&#xD;
          -  15)Grade III or above myelosuppression (WBC &lt; 1.9) × 109 / L, hemoglobin lower than 79&#xD;
             g / L, platelet lower than 49 g / L × 109/L）&#xD;
&#xD;
          -  16)Severe liver dysfunction, serum albumin less than 28 g/L, or serum bilirubin more&#xD;
             than 50 μmol/L, or serum alanine transferase was 1.5 times higher than normal&#xD;
&#xD;
          -  17)HIV positive (HIV 1/2 anti-body)&#xD;
&#xD;
          -  18)Live vaccine is administered less than 30 days before or possibly during the study&#xD;
             period;&#xD;
&#xD;
          -  19)The subject has a known history of psychotropic substance abuse, alcohol abuse or&#xD;
             drug abuse;&#xD;
&#xD;
          -  20)Researchers think that should be left out in this study, the researchers determine,&#xD;
             for example, the subjects have other factors that may result in this study were forced&#xD;
             to midway termination, such as, other serious disease (including mental illness) need&#xD;
             to merge treatment, there are serious abnormal laboratory examination, accompanied by&#xD;
             factors such as family or society, will affect the safety of the subjects, or&#xD;
             information and the collection of the sample.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingbo Liang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xueli Bai, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiwen Chen, Dr.</last_name>
    <phone>+86 19941463683</phone>
    <email>yiwenchen0705@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TingBo Liang, MD, PHD</last_name>
      <phone>086-571-87236688</phone>
      <email>liangtingbo@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>TingBo Liang</investigator_full_name>
    <investigator_title>The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

